The week's news included the differences in public attitudes towards influenza and COVID-19 vaccines, sex-based differences in direct-acting antivirals, a request for an emergency use authorization for a monoclonal antibody for COVID-19 prevention in the immunocompromised, and our final episode of our RSV Roundtable series, which has clinicians weighing in on the importance of counseling patients on the immunizations now and their significance for the future.
Monthly elebsiran plus tobevibart achieved undetectable HDV RNA with ALT normalization in 44% of patients at week 48 in the pivotal phase 3 ECLIPSE 1 trial.
Charles M. Walworth, MD, of Labcorp discusses a new hepatitis D reflex pathway, internal data showing 8.3% of HBsAg-positive patients screened for HDV, and lessons from hepatitis C reflex testing.
IDSA and ESCMID released 7 consensus statements to assist in managing individuals with SAB. This review will focus on the adult patient population and additional information on pediatric population statements can be assessed in the guideline. Here is a closer look at Consensus Statement 2: Follow-up Blood Cultures.
IDSA and ESCMID released 7 consensus statements to assist in managing individuals with Staphylococcus aureus Bacteremia (SAB). This review will focus on the adult patient population and additional information on pediatric population statements can be assessed in the guideline.
New data from the PETERPEN trial suggest that piperacillin-tazobactam may be noninferior to meropenem for early clinical outcomes in select patients with ESBL bloodstream infections, but carbapenems remain the standard of care until final mortality results are available and fully analyzed.
Recent urinary tract infection guideline updates from multiple international
medical societies highlight evolving recommendations, including a major shift
in classification, moving from anatomy- and risk factor–based definitions
toward distinguishing localized from systemic infections.